focus -WSS

focus

author：hotspot 2025-09-02 22:20:44 - browse：52923

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： UnitedHealth quietly bought dozens of outpatient centers

Wikipedia

WSS

The biotech scorecard for Q4: 16 stock

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Headspace, Meta partner to launch VR meditation app for Quest

Experts study whether long Covid risk adds up with each reinfection

Amylyx ALS drug fails large clinical trial

European officials brace for rough respiratory virus season

leisure time

focus

explore

Heart attack and stroke risk calculators need revising

The stability of $0 premiums in Medicare Advantage

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

IVG is promising — but it won’t replace IVF quite yet

Drug repurposing or repositioning? The language matters

The biotech scorecard for Q4: 16 stock

In Memoriam: Notable people who died in 2023

The Karikó problem: Lessons for funding basic research

Cancer drug shortages should be causing more outrage

Congress extends some pandemic preparedness programs

knowledge

The Readout: Amylyx, Alumis, and Lundbeck drug updates

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Sen. Paul opposes bill to ban Chinese biotechs

New oral drug delivery patch is modeled after octopus tentacles

Setback for rare diseases as Taysha Gene Therapies pulls back

CRISPR base editing slashes cholesterol levels in monkeys

hotspot

Wikipedia

focus

hotspot